Buscar en
Medicina Clínica (English Edition)
Toda la web
Inicio Medicina Clínica (English Edition) Effect of antiresorptive and bone forming treatments in bone erosions in rheumat...
Journal Information
Vol. 154. Issue 9.
Pages 358-365 (May 2020)
Share
Share
Download PDF
More article options
Visits
3
Vol. 154. Issue 9.
Pages 358-365 (May 2020)
Review
Effect of antiresorptive and bone forming treatments in bone erosions in rheumatoid arthritis
Efecto del tratamiento antirresortivo y osteoformador en las erosiones óseas en la artritis reumatoide
Visits
3
Ana Belén Azuaga-Piñangoa,
Corresponding author
abazuaga@clinic.cat

Corresponding author.
, Pilar Perisa,b
a Servicio de Reumatología, Hospital Clínic, Universidad de Barcelona, Barcelona, Spain
b CIBERehd, Barcelona, Spain
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Tables (3)
Table 1. Characteristics of clinical studies on the effect of denosumab on bone erosions.
Table 2. Characteristics of clinical studies on the effect of bisphosphonates on bone erosions.
Table 3. Characteristics of clinical studies on the effect of teriparatide on bone erosions.
Show moreShow less
Abstract

Rheumatoid arthritis (RA) is a chronic inflammatory disease that can cause joint destruction and marked disability. Early treatment with disease-modifying drugs, including biological therapy, is the principal treatment to prevent the structural damage associated with this entity. Some studies have indicated that concomitant treatment with antiresorptives, such as bisphosphonates or denosumab, could prevent erosive lesions in this process, and it has even been suggested that treatment with a bone forming agent, such as teriparatide, could revert previously established erosive lesions. In this article we review the evidence available on the efficacy of treatment with antiresorptives and bone forming agents in the prevention and/or treatment of bone erosions associated with RA.

Keywords:
Rheumatoid arthritis
Bone erosion
Denosumab
Bisphosphonate
Teriparatide
Osteoporosis
Zoledronic acid
Resumen

La artritis reumatoide (AR) es una enfermedad inflamatoria crónica que puede ocasionar destrucción articular y marcada discapacidad. El tratamiento precoz con fármacos modificadores de la enfermedad, incluyendo la terapia biológica, constituye el principal tratamiento para prevenir el daño estructural asociado a esta entidad. Algunos estudios han indicado que el tratamiento concomitante con antirresortivos, como los bisfosfonatos o el denosumab, podría prevenir el desarrollo de lesiones erosivas en este proceso, e incluso se ha sugerido que el tratamiento con un osteoformador, como la teriparatida, podría revertir las lesiones erosivas previamente establecidas. En este artículo se revisa la evidencia disponible sobre la eficacia del tratamiento antirresortivo y osteoformador en la prevención o tratamiento de las erosiones óseas asociadas a la AR.

Palabras clave:
Artritis reumatoide
Erosiones óseas
Denosumab
Bisfosfonatos
Teriparatida
Osteoporosis
Zoledronato

Article

These are the options to access the full texts of the publication Medicina Clínica (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Medicina Clínica (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.medcle.2023.07.008
No mostrar más